{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:21:35Z","timestamp":1792624895204,"version":"4.5.0"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Bacteremia is the second leading cause of death in patients with end-stage renal disease who are on hemodialysis. A vaccine eliciting long-term immune responses against\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            in patients on chronic hemodialysis may reduce the incidence of bacteremia and its complications in these patients. V710 is a vaccine containing iron surface determinant B (IsdB), a highly conserved\n            <jats:named-content content-type=\"genus-species\">S. aureus<\/jats:named-content>\n            surface protein, which has been shown to be immunogenic in healthy subjects. In this blinded phase II immunogenicity study, 206 chronic hemodialysis patients between the ages of 18 and 80 years old were randomized to receive 60 \u03bcg V710 (with or without adjuvant), 90 \u03bcg V710 (with adjuvant), or a placebo in various combinations on days 1, 28, and 180. All 201 vaccinated patients were to be followed through day 360. The primary hypothesis was that at least 1 of the 3 groups receiving 2 V710 doses on days 1 and 28 would have a \u22652.5 geometric mean fold rise (GMFR) in anti-IsdB IgG titers over the baseline 28 days after the second vaccination (day 56). At day 56, all three groups receiving 2 doses of V710 achieved a \u22652.5 GMFR in anti-IsdB antibodies compared to the baseline (\n            <jats:italic>P<\/jats:italic>\n            values of &lt;0.001 for all 3 groups), satisfying the primary immunogenicity hypothesis. None of the 33 reported serious adverse experiences were considered vaccine related by the investigators. V710 induced sustained antibody responses for at least 1 year postvaccination in patients on chronic hemodialysis.\n          <\/jats:p>","DOI":"10.1128\/cvi.00034-12","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T04:38:15Z","timestamp":1343277495000},"page":"1509-1516","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["Phase IIa Study of the Immunogenicity and Safety of the Novel Staphylococcus aureus Vaccine V710 in Adults with End-Stage Renal Disease Receiving Hemodialysis"],"prefix":"10.1128","volume":"19","author":[{"given":"Moustafa","family":"Moustafa","sequence":"first","affiliation":[{"name":"South Carolina Nephrology &amp; Hypertension Center, Orangeburg, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Aronoff","sequence":"additional","affiliation":[{"name":"University of Louisville School of Medicine, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Chandran","sequence":"additional","affiliation":[{"name":"St. Joseph's Regional Medical Center, Paterson, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Hartzel","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp., Whitehouse Station, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S.","family":"Smugar","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp., Whitehouse Station, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude M.","family":"Galphin","sequence":"additional","affiliation":[{"name":"Southeastern Renal Research Institute, Chattanooga, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel U.","family":"Mailloux","sequence":"additional","affiliation":[{"name":"Hofstra North Shore-LIJ School of Medicine, Port Washington, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Brown","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp., Whitehouse Station, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"DiNubile","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp., Whitehouse Station, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Kartsonis","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp., Whitehouse Station, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalya","family":"Guris","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme Corp., Whitehouse Station, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0272-6386(85)80021-4","article-title":"Hepatitis B virus vaccine: a randomized trial of a reduced dose regimen in hemodialysis patients","volume":"6","author":"Aronoff GR","year":"1985","unstructured":"AronoffGRMaxwellDRBatteigerBEFinebergNS. 1985. Hepatitis B virus vaccine: a randomized trial of a reduced dose regimen in hemodialysis patients. Am. J. Kidney Dis. 6:170\u2013172.","journal-title":"Am. J. Kidney Dis."},{"key":"e_1_3_2_3_2","first-page":"197","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005","volume":"56","author":"Centers for Disease Control","year":"2007","unstructured":"Centers for Disease Control. 2007. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR Morb. Mortal. Wkly. Rep. 56:197\u2013199.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir828"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1086\/502580","article-title":"Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis","volume":"26","author":"Engemann JJ","year":"2005","unstructured":"EngemannJJ. 2005. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect. Control Hosp. Epidemiol. 26:534\u2013539.","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"e_1_3_2_6_2","unstructured":"FowlerVG. 2012. Efficacy and safety of V710 a Staphylococcus aureus vaccine in preventing bacteraemia and\/or deep sternal wound infections in patients undergoing cardiac surgery abstr O164. Abstr. 22nd Eur. Congr. Infect. Dis. Clin. Microbiol. London United Kingdom; 31 March to 3 April 2012. http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1469-0691.2012.03801.x\/pdf."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/0272-6386(95)90491-3","article-title":"Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure","volume":"26","author":"Girndt M","year":"1995","unstructured":"GirndtMPietschMKohlerH. 1995. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am. J. Kidney Dis. 26:454\u2013460.","journal-title":"Am. J. Kidney Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00356-10"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2011.12.045","article-title":"The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two phase I studies","volume":"30","author":"Harro C","year":"2012","unstructured":"HarroC. 2012. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two phase I studies. Vaccine 30:1729\u20131736.","journal-title":"Vaccine"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.5.2742-2750.2006"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ki.1997.322","article-title":"Low efficiency of active immunization against diphtheria in chronic hemodialysis patients","volume":"52","author":"Kreft B","year":"1997","unstructured":"KreftBKloucheMKreftRKirchnerHSackK. 1997. Low efficiency of active immunization against diphtheria in chronic hemodialysis patients. Kidney Int. 52:212\u2013216.","journal-title":"Kidney Int."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.4.2215-2223.2006"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2215\/CJN.03760708","article-title":"Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients","volume":"4","author":"Li Y","year":"2009","unstructured":"LiY. 2009. Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin. J. Am. Soc. Nephrol. 4:428\u2013434.","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1681\/ASN.2007090971","article-title":"Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients","volume":"19","author":"Litjens NH","year":"2008","unstructured":"LitjensNHHuismanMvan den DorpelMBetjesMG. 2008. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J. Am. Soc. Nephrol. 19:1483\u20131490.","journal-title":"J. Am. Soc. Nephrol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1073\/pnas.032523999","article-title":"An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis","volume":"99","author":"Mazmanian SK","year":"2002","unstructured":"MazmanianSKTon-ThatHSuKSchneewindO. 2002. An iron-regulated sortase anchors a class of surface protein during Staphylococcus aureus pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 99:2293\u20132298.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/j.ajkd.2005.04.019","article-title":"Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis","volume":"46","author":"Nissenson AR","year":"2005","unstructured":"NissensonAR. 2005. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am. J. Kidney Dis. 46:301\u2013308.","journal-title":"Am. J. Kidney Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"PancariG. 2012. Characterization of the mechanism of protection mediated by CS-D7 a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB). Front. Cell. Infect. Microbiol. 2:36. doi:10.3389\/fcimb.2012.00036.","DOI":"10.3389\/fcimb.2012.00036"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1016\/j.vaccine.2011.11.006","article-title":"Is there a future for a Staphylococcus aureus vaccine","volume":"30","author":"Proctor RA","year":"2012","unstructured":"ProctorRA. 2012. Is there a future for a Staphylococcus aureus vaccine? Vaccine 30:2921\u20132927.","journal-title":"Vaccine"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF01644539","article-title":"Influenza subtype-specific IgA, IgM and IgG responses in patients on hemodialysis after influenza vaccination","volume":"16","author":"Rautenberg P","year":"1988","unstructured":"RautenbergPTeifkeISchlegelbergerTUllmannU. 1988. Influenza subtype-specific IgA, IgM and IgG responses in patients on hemodialysis after influenza vaccination. Infection 16:323\u2013328.","journal-title":"Infection"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1086\/502523","article-title":"Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia","volume":"26","author":"Reed SD","year":"2005","unstructured":"ReedSD. 2005. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. 26:175\u2013183.","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa011297","article-title":"Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis","volume":"346","author":"Shinefield HS","year":"2002","unstructured":"ShinefieldHS. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346:491\u2013496.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_22_2","volume-title":"United States Renal Data System 2006 annual data report: atlas of end-stage renal disease in the United States.","author":"United States Renal Data System","year":"2006","unstructured":"United States Renal Data System. 2006. United States Renal Data System 2006 annual data report: atlas of end-stage renal disease in the United States. U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00034-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00034-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:48:21Z","timestamp":1627591701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00034-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1128\/CVI.00034-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00034-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"2012-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}